Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pelviprost Compresse is an oral nutraceutical developed by Epitech Group, formulated with micronized and ultramicronized palmitoylethanolamide (PEA) and polydatin. As an ALIAmide-based product, it functions by modulating the activity of mast cells and other non-neuronal immune cells, such as microglia and astrocytes, to control neuroinflammation and peripheral nerve sensitivity. It is primarily indicated for the management of neuroinflammatory disorders of the pelvic area, including chronic prostatitis, benign prostatic hyperplasia (BPH), lower urinary tract symptoms (LUTS), and chronic pelvic pain. The product is marketed in Italy as a food supplement to promote the restoration of normal physiological reactivity in prostatic tissue.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pelviprost compresse.